

Cannabinoid R&D and clinical trial expert appointed to AusCann Board

Highlights

- Dr. Bonn-Miller, Global Clinical Scientific Director of Spectrum Therapeutics, the medical division of Canopy Growth Corporation, with extensive world-class experience in cannabinoids research, pharmaceutical development and clinical trials worldwide, appointed to AusCann Board
- Appointment of Dr. Bonn-Miller as Non-Executive Director, replaces Mr. Bruce Linton as nominee for AusCann's largest shareholder Canopy Growth
- The changes reflect the continued commitment and collaboration between AusCann and Canopy Growth to better serve patients through validated cannabinoid-based medicines

5 September 2019 – Leading medical cannabis company **AusCann Group Holdings Limited** (ASX:AC8) (AusCann or 'the Company') advises that cannabinoid expert and medical executive, Dr. Marcel Bonn-Miller, has been appointed to the AusCann Board as a Non-Executive Director, with effect from today.

Dr. Bonn-Miller will replace Mr. Bruce Linton as nominee Director for AusCann's largest shareholder Canopy Growth Corporation ('Canopy Growth') who steps down from his role as a Non-Executive Director of AusCann, also effective today. Mr. David Pryce, who acted as Alternate Director for Mr. Bruce Linton, has also resigned today.

Dr. Bonn-Miller is Global Clinical Scientific Director of Spectrum Therapeutics, the medical division of Canopy Growth specialised in the development and commercialisation of validated cannabis medicines. Dr. Bonn-Miller is a world-renowned researcher and pharmaceutical executive, bringing over 18 years of extensive clinical research and development expertise in cannabinoid-products for medical use. He has received funding for 27 research grants, has published 140 peer-reviewed academic papers and has led or contributed to 19 clinical trials. Prior to Canopy Growth, Dr. Bonn-Miller was Director of Cannabinoid Research for Zynerva Pharmaceuticals, a leading transdermal cannabinoid pharmaceutical company.

AusCann Chairman Dr. Mal Washer commented: "We are delighted to welcome Marcel to the Board. As a worldwide expert in the clinical use of cannabinoid-based medicines and with a wealth of medical, product development and research experience, he is uniquely placed to assist the Board with his strategic vision going forward.

"On behalf of the Board, I would also like to sincerely thank Bruce Linton and David Pryce for their invaluable guidance and contribution to the business since AusCann's early listing days.

"We are committed to positioning AusCann as a trusted pharmaceutical company. Providing reliable and dose consistent cannabinoid-based pharmaceutical products to patients, whilst building awareness and acceptance in the medical community of their benefits and clinical outcomes is how we will succeed in our strategy, and improve patients' quality of life."

ENDS

For more information, please contact:

For Investment Enquiries

Quentin Megson
Chief Operating and Financial Officer
info@auscann.com.au
+61 8 9561 8834

For Media Enquiries

Elodie Castagna
FTI Consulting
elodie.castagna@fticonsulting.com
+61 8 9321 8533

ABOUT AUSCANN

AusCann Group Holdings Limited (ASX:AC8) is an Australian-based Pharmaceutical Company focused on the development, production, and marketing of cannabinoids-based pharmaceuticals within Australia and internationally. AusCann:

- **transforms** the way Medical Cannabis is dispensed today by making Cannabinoids-based Pharmaceutical dose forms accessible to patients, physicians and healthcare providers worldwide.
- **enables** physicians to treat their patients with a reliable, stable, well-characterized pharmaceutical product, monitor treatment results and adjust treatment algorithm using a portfolio of products and formulations.
- **holds** all required Medical Cannabis licenses to operate in Australia following its incorporation in 2014.
- **is targeting** the treatment of chronic pain in Australia initially, whilst exploring global export opportunities and expansion into additional medical areas.